Novartis Might Struggle to Clear Bar in Cholesterol Drug Trial

Dow Jones15:29

0729 GMT - Novartis's odds of success in a late-stage trial for cholesterol-lowering drug pelacarsen seem in the balance, analysts at J.P. Morgan say in a note. For the trial to be successful, the Swiss drugmaker likely needs the medicine to cut cardiovascular risk by 13% in the overall population and by 15% in patients with at least 90 milligrams per deciliter of lipoprotein(a)--a variant of the so-called bad cholesterol--in their blood, according to JPM. The analysts see a 40% chance of this happening. "Even if the trial was successful, we see the ultimate commercial opportunity as relatively limited given a borderline statistically significant result is unlikely to be seen as sufficiently clinically meaningful to support adoption of Lp(a) testing and widespread use of an additional therapy," they add. Novartis shares rise 0.3%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment